Your browser doesn't support javascript.
loading
Development of a high-dose vaccine formulation for prevention of megalocytivirus infection in rock bream (Oplegnathus fasciatus).
Kwon, Woo Ju; Choi, Jae Chan; Hong, Suhee; Kim, Young Chul; Jeong, Min Gyeong; Min, Joon Gyu; Jeong, Joon Bum; Kim, Kwang Il; Jeong, Hyun Do.
Afiliação
  • Kwon WJ; Department of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea.
  • Choi JC; Gyeongsangbuk-do Fisheries Technology Center, Pohang, 37556, Republic of Korea.
  • Hong S; Department of Marine Biotechnology, Gangneung-Wonju National University, Gangneung 25457, Republic of Korea.
  • Kim YC; National Fishery Products Quality Management Service, Busan 49111, Republic of Korea.
  • Jeong MG; Department of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea.
  • Min JG; Department of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea.
  • Jeong JB; Department of Aquatic Biomedical Science, Jeju National University, Jeju 63243, Republic of Korea.
  • Kim KI; Department of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea. Electronic address: kimki@pknu.ac.kr.
  • Jeong HD; Department of Aquatic Life Medicine, Pukyong National University, Busan 48513, Republic of Korea.
Vaccine ; 38(51): 8107-8115, 2020 12 03.
Article em En | MEDLINE | ID: mdl-33189430
ABSTRACT
A formalin-inactivated red sea bream iridovirus (RSIV) vaccine was prepared using the culture supernatant of a persistently infected Pagrus major fin cell line (PI-PMF) with IVS-1 strain (RSIV subtype II Meglaocytivirus). Rock bream (Oplegnathus fasciatus) were injected with a high-dose, ultracentrifuged megalocytivirus vaccine (Ultra HSCMV, 7.0 × 1010 copies/mL), a high-dose supernatant of cultured megalocytivirus vaccine (HSCMV, 1.0 × 1010 copies/mL), a supernatant of cultured megalocytivirus vaccine (SCMV, 1.0 × 109 copies/mL), and a low-dose of cultured megalocytivirus vaccine (LSCMV, 1.0 × 108 copies/mL). The vaccine efficacies for the various vaccine formulations were determined done following injection challenge with IVS-1 (1.0 × 104 copies/0.1 mL/fish), and the four different vaccines exhibited cumulative mortalities of 10.0 ± 0.0%, 48.3 ± 7.6%, 75.0 ± 5.0%, and 100.0 ± 0.0%, respectively. Additionally, the dose-dependent vaccine efficacy was also confirmed using two different cohabitation methods that included challenges G (general) and I (individual). When squalene + aluminum hydroxide (SqAl) was used as an adjuvant for the HSCMV or SCMV vaccine, cumulative mortalities of 30.0 ± 5.0% and 48.3 ± 7.6%, respectively, were obtained; moreover, these two adjuvants exhibited the highest efficacy in this study. The observed difference in survival post-challenge for the different vaccine concentrations was not reflected in the differences in neutralizing antibody titers. It was found that the water temperature during immune induction plays a less important a role than the water temperature during the challenge test, in which lowering the water temperature from 25 °C to 21 °C during a challenge improved the level of protection from cumulative mortalities from 35% to 10%. This study demonstrated that protection against mortality using inactivated vaccines against RSIVD in rock bream, which are known to be the most susceptible species to RSIV infection, is dependent upon antigen dose and temperature during the challenge.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Perciformes / Vacinas / Infecções por Vírus de DNA / Doenças dos Peixes / Iridoviridae Limite: Animals Idioma: En Revista: Vaccine Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Perciformes / Vacinas / Infecções por Vírus de DNA / Doenças dos Peixes / Iridoviridae Limite: Animals Idioma: En Revista: Vaccine Ano de publicação: 2020 Tipo de documento: Article
...